Sanofi and Alnylam pact moves from research to delivery

8 April 2019

The research phase of the RNAi therapeutics collaboration between Sanofi (Euronext: SAN) and Alnylam Pharmaceuticals (Nasdaq: ALNY) is over, the companies have announced.

In January 2018, the companies amended their agreement so that Sanofi would obtain global development and commercialization rights to the hemophilia candidate fitusiran, and pay Alnylam royalties on sales, while the US biotech would be in the box seat with Onpattro (patisiran) and follow-up hATTR amyloidosis therapy vutrisiran ALN-TTRsc02 and would pay royalties to the French drugmaker on sales.

While the companies will now stop working together on research, Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease through the end of IND-enabling studies, after which Sanofi will be responsible for any potential further development or commercialization of the drug, paying royalties to the Boston-based firm.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK